Work

Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab in treatment-naive advanced/metastatic (adv/met) non–small cell lung cancer (NSCLC) with PD-L1 ≥ 50% and without actionable genomic alterations.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps3162

Authors: Benjamin Philip Levy, Martin Reck, James Chih-Hsin Yang, Federico Cappuzzo, Siddhartha Rawat, Jingdong Xie, Priyanka Basak, Enriqueta Felip

Institutions: Sidney Kimmel Cancer Center, German Center for Lung Research, LungenClinic Grosshansdorf, National Taiwan University, National Taiwan University Hospital, Instituto Nazionale Tumori Regina Elena, Daiichi Sankyo (United States), Vall d'Hebron Institute of Oncology

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286294885

Cites:

Cited by: 5

Related to: 10